Two phase 1 trials of single IV rimteravimab (250–1,000 mg) in 30 healthy adults (placebo-controlled) and 27 patients hospitalised with mild-to-moderate COVID-19 (open-label) found no treatment-related serious adverse events and no clear dose-response in clinical status.
RCTn = 57
Jansen et al. Characterization of the VHH-Fc construct rimteravimab in healthy adults and patients hospitalized for mild-to-moderate COVID-19: Two Phase 1 randomized clinical trials